Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0847097 (
acidity
)
15,165
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Under the standard conditions of culture, Fru-2,6-P2 level in HT29 cells is transitorily increased as a consequence of medium change; the peak value occurs after 2 hr, followed by a gradual return to a basal value (40 pmol/mg protein) which is maintained as long as medium glucose concentration stands above 2 mM. A 20 hr glucose deprivation lowers Fru-2,6-P2 level to trace value, but, when glucose is reintroduced, the peak value is much higher; large Fru-2,6-P2 accumulation is correlated with higher rates of glucose uptake and lactate release, which suggests an activation of glycolysis at the level of phosphofructokinase-1. Fru-2,6-P2 level depends on the glucose concentration within the range of 0 to 5 mM. At this concentration and above, maximal effect is reached. Previous glucose deprivation renders the Fru-2,6-P2 forming system more sensitive to glucose. When given instead of glucose, fructose enters the glycolytic pathway and produces same effect as glucose on the Fru-2,6-P2 level.
Galactose
turns it to almost zero which coincides with low glycolytic rate.
Acidity
of the culture medium favorishes the Fru-2,6-P2 formation; however, change in pH cannot explain the variations of Fru-2,6-P2 level observed under the standard culture conditions. Lactate concentrations over 10 mM in the medium are found to significantly inhibit the Fru-2,6-P2 producing system. Therefore, lactate accumulation in the medium could be an important factor controlling Fru-2,6-P2 level during standard cell culture.
...
PMID:Variations of fructose-2,6-diphosphate levels in cultured HT29 human colon cancer cells: influence of hexoses and lactate concentrations. 381 73
Fermentation of lactose in whey permeate directly into ethanol has had only limited commercial success, as the yields and alcohol tolerances of the organisms capable of directly fermenting lactose are low. This study proposes an alternative strategy: treat the permeate with acid to liberate monomeric sugars that are readily fermented into ethanol. We identified optimum hydrolysis conditions that yield mostly monomeric sugars and limit formation of fermentation inhibitors such as hydroxymethyl furfural by caramelization reactions. Both lactose solutions and commercial whey permeates were hydrolyzed using inorganic acids and carbonic acid. In all cases, more glucose was consumed by secondary reactions than galactose.
Galactose
was recovered in approximately stoichiometric proportions. Whey permeate has substantial buffering capacity-even at high partial pressures (>5500 kPa[g]), carbon dioxide had little effect on the pH in whey permeate solutions. The elevated temperatures required for hydrolysis with CO2-generated inhibitory compounds through caramelization reactions. For these reasons, carbon dioxide was not a feasible acidulant. With mineral acids reversion reactions dominated, resulting in a stable amount of glucose released. However, the Maillard browning reactions also appeared to be involved. By applying Hammet's
acidity
function, kinetic data from all experiments were described by a single line. With concentrated inorganic acids, low reaction temperatures allowed lactose hydrolysis with minimal by-product formation and generated a hexose-rich solution amenable to fermentation.
...
PMID:Hydrolysis of lactose in whey permeate for subsequent fermentation to ethanol. 1545 74
Multi-layered nanocomplexes (MLNs) were designed here to provide smart co-delivery of doxorubicin (DOX) and vascular endothelial growth factor (VEGF) siRNA. The electrostatically self-assembled MLNs were constructed by TAT peptide modified mesoporous silica nanoparticles (TAT-MSN) as the cationic core for DOX loading, poly(allylamine hydrochloride)-citraconic anhydride (PAH-Cit) as the anionic inner layer, and galactose-modified trimethyl chitosan-cysteine (GTC) conjugate as the cationic outer layer to encapsulate siRNA. Their strong stability at pH 7.4 and 6.5 protected siRNA from degradation in the blood and tumor microenvironment.
Galactose
ligands on the GTC outer layers effectively facilitated the internalization of MLNs through receptor-mediated endocytosis. Afterwards, the endosomal/lysosomal
acidity
(pH 5.0) triggered the charge reversal of PAH-Cit, thereby inducing the disassembly of MLNs and their escape to the cytosol. Cytoplasmic glutathione further accelerated siRNA release through cleaving disulfide bonds in GTC layers, leading to high silencing efficiencies. Meanwhile, the exposed DOX-loaded cores were transported into the nuclei by virtue of TAT peptide and exhibited sustained release thereafter. As a result, potent antitumor efficacies of MLNs were noted following intravenous injection at a low dose with no apparent toxicity detected. Therefore, MLNs served as an effective and safe vector to maximize synergistic effect of chemodrugs and therapeutic genes.
...
PMID:Dual-targeting and pH/redox-responsive multi-layered nanocomplexes for smart co-delivery of doxorubicin and siRNA. 2598 52